AbCellera宣布其治疗更年期血管舒缩症状药物Abcl635的1/2期临床试验进入第二阶段

美股速递
Jan 12

AbCellera Biologics宣布,其针对更年期血管舒缩症状的候选药物Abcl635,在1/2期临床试验中已完成第一阶段,并已启动第二阶段,首批患者已接受给药。这一进展标志着该药物研发进入新阶段,旨在评估Abcl635在更广泛患者群体中的疗效与安全性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10